A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation

There is no direct evidence comparing the 2 most commonly prescribed direct oral anticoagulants, apixaban and rivaroxaban, used for stroke prevention in nonvalvular atrial fibrillation (NVAF). A number of network meta-analyses (NMAs) of randomized control trials and real-world evidence (RWE) studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Nathan R., Sandler, Belinda, Bergrath, Evelien, Milenković, Dušan, Ashaye, Ajibade O., Farooqui, Usman, Cohen, Alexander T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098208/
https://www.ncbi.nlm.nih.gov/pubmed/31918558
http://dx.doi.org/10.1177/1076029619898764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098208/
https://www.ncbi.nlm.nih.gov/pubmed/31918558
http://dx.doi.org/10.1177/1076029619898764

Ejemplares similares